galinpepimut-s: mechanism of action and use in aml, ovarian cancer & mesothelioma
Published 2 years ago • 587 plays • Length 9:15Download video MP4
Download video MP3
Similar videos
-
27:39
novel therapeutics in ovarian cancer: what to watch
-
50:04
ovarian cancer update - parvin f. peddi, md | ucla health
-
29:51
evaluating clinical pathways for ovarian cancer treatment and maintenance therapy
-
6:14
standard of care and progress with parp inhibitors for ovarian cancer
-
4:12
understanding ovarian cancer
-
2:58
standard of care updates in ovarian cancer: parp inhibitors
-
2:55
prognostic drivers in aml and mds
-
1:12
where is ovarian cancer treatment headed?
-
1:56
gps and nps: novel immunotherapeutics from sellas
-
1:05
dr. pietras discusses pain management in ovarian cancer
-
0:50
checkpoint inhibition in mesothelioma: the confirm trial
-
1:22
dr. glaspy on immunogenicity in ovarian cancer
-
1:38
the potential of menin inhibitors in specific molecular subsets of aml & all
-
12:46
breakthrough designation in aml, application submitted in myeloma, promising data in sclc, and more
-
1:42
developments in prognostic factors of acute myeloid leukemia (aml)
-
4:08
selecting optimal upfront therapy for ovarian cancer
-
2:02
isal session highlights: targeting cd123, cd47 & tp53 in aml
-
3:18
the impact of secondary aml mutations on the prognosis of patients with npm1-mutated aml
-
9:12
ovarian cancer explained (including subtypes)